Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology
company developing a liposomal delivery technology for nucleic acid
cancer drugs, today announced that data from pre-clinical studies of
BP-100-1.01 (Liposomal Grb-2) were featured in the peer-reviewed journal Expert
Opinion on Drug Delivery.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.